tbuckley/cabot-search huggingface dataset:
Risk and impact of renal impairment of locally advanced head and neck squamous cell carcinoma patients who received chemoradiotherapy with cisplatin
Authors: T. Patimarattananan, P. Pattaranutaporn, N. Unwanatham, C. Jiarpinitnun, A. Nongnuch, N. Ngamphaiboon
Journal: Annals of Oncology (2019)
Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Authors: A. Memarian, H. Samiei, B. Sedighi-Moghaddam, S. Mohammadi, A. Gharavi, S. Abdolmaleki, M. Jeddi-Tehrani
Journal: Annals of Oncology (2019)
Allogeneic Stem Cell Transplantation from Unrelated Donors within the Seventh Decade of Life.
Authors: Joachim Dahlke, Tatjana Zabelina, Francis Ayuk, Jens Panse, Heike Schieder, Helmut Renges, Djorde Atanackovic, Christine Wolschke, Axel R. Zander, Nicolaus Kroeger
Journal: Blood (2005)
Effects of the Gamma Secretase Inhibitors (GSI) Dapt (GSI-IX) and LSN424354 on Gene Expression and Shedding of Bcma from Multiple Myeloma and Chronic Lymphocytic Leukemia Tumor Cells
Authors: Haiming Chen, Mingjie Li, Eric Sanchez, Camilia Soof, Saurabh Patil, Kyle Udd, Mizi Zhou, Tara Hekmati, Emily Y Wang, Edward J Tanenbaum, Remy Schlossberg, Moryel A Yashar, Cathy S Wang, George Y Tang, James R Berenson
Journal: Blood (2017)
A deep learning framework for neuroscience
Authors: Blake A. Richards, Timothy P. Lillicrap, Philippe Beaudoin, Yoshua Bengio, Rafal Bogacz, Amelia Christensen, Claudia Clopath, Rui Ponte Costa, Archy de Berker, Surya Ganguli, Colleen J. Gillon, Danijar Hafner, Adam Kepecs, Nikolaus Kriegeskorte, Peter Latham, Grace W. Lindsay, Kenneth D. Miller, Richard Naud, Christopher C. Pack, Panayiota Poirazi, Pieter Roelfsema, João Sacramento, Andrew Saxe, Benjamin Scellier, Anna C. Schapiro, Walter Senn, Greg Wayne, Daniel Yamins, Friedemann Zenke, Joel Zylberberg, Denis Therien, Konrad P. Kording
Journal: Nature Neuroscience (2019)
Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015
Authors: A Bujosa Rodríguez, J.C. Tapia, T. Hwang, C Molto Valiente, A.J. Templeton, A. Barnadas, E. Amir, A. Tibau
Journal: Annals of Oncology (2019)
Microarray of Bone Marrow CD34+/Lin- Cells from Patients with Chronic Myeloid Leukemia (CML)
Authors: Alessandra Trojani, Milena Lodola, Barbara Di Camillo, Giuseppe Rossi, Adele Capucci, Alessandra Perego, Enrico Maria Pogliani, Ester Orlandi, Alessandra Iurlo, Simona Malato, Paolo Corradini, Roberto Cairoli, Marco Bregni, Sergio Pauli, Enrica Morra, Ester Pungolino
Journal: Blood (2014)
A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Authors: H.L. McArthur, E.A. Comen, Y. Bryce, S.B. Solomon, J.H.S. Leal, M. Rodine, C.D. Abaya, S. Patil, D.B. Page, L. Norton
Journal: Annals of Oncology (2019)
Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Authors: A.O. Siefker-Radtke, I. Lugowska, K. Tupikowski, Z.G. Andric, A. Rezazadeh Kalebasty, G. Curigliano, D. Vaena, F.D. Vogl, G. Currie, S. Abella, W. Kelly
Journal: Annals of Oncology (2019)
Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
Authors: S.M. Gadgeel, T.S.K. Mok, S. Peters, J.A.A. Alexander, N.B. Leighl, V. Sriuranpong, M. Perol, G. De Castro, E. Nadal, F. De Marinis, J.-Y. Han, M. Yan, T. Riehl, E. Schleifman, S.M. Paul, S. Mocci, D. Shames, M.S. Mathisen, R. Dziadziuszko
Journal: Annals of Oncology (2019)
A rectal cancer organoid platform to study individual responses to chemoradiation
Authors: Karuna Ganesh, Chao Wu, Kevin P. O’Rourke, Bryan C. Szeglin, Youyun Zheng, Charles-Etienne Gabriel Sauvé, Mohammad Adileh, Isaac Wasserman, Michael R. Marco, Amanda S. Kim, Maha Shady, Francisco Sanchez-Vega, Wouter R. Karthaus, Helen H. Won, Seo-Hyun Choi, Raphael Pelossof, Afsar Barlas, Peter Ntiamoah, Emmanouil Pappou, Arthur Elghouayel, James S. Strong, Chin-Tung Chen, Jennifer W. Harris, Martin R. Weiser, Garrett M. Nash, Jose G. Guillem, Iris H. Wei, Richard N. Kolesnick, Harini Veeraraghavan, Eduardo J. Ortiz, Iva Petkovska, Andrea Cercek, Katia O. Manova-Todorova, Leonard B. Saltz, Jessica A. Lavery, Ronald P. DeMatteo, Joan Massagué, Philip B. Paty, Rona Yaeger, Xi Chen, Sujata Patil, Hans Clevers, Michael F. Berger, Scott W. Lowe, Jinru Shia, Paul B. Romesser, Lukas E. Dow, Julio Garcia-Aguilar, Charles L. Sawyers, J. Joshua Smith
Journal: Nature Medicine (2019)
Alpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial
Authors: M. Campone, H.S. Rugo, G. Rubovszky, F. André, S. Loibl, H. Iwata, P.F. Conte, I. Mayer, D. Juric, T. Yamashita, I. Lorenzo, A. Ridolfi, E.M. Ciruelos
Journal: Annals of Oncology (2019)
LncRNA-<i>Safe</i> contributes to cardiac fibrosis through <i>Safe</i>-<i>Sfrp2</i>-HuR complex in mouse myocardial infarction
Authors: Kaili Hao, Wei Lei, Hongchun Wu, Jie Wu, Zhuangzhuang Yang, Shiping Yan, Xing-Ai Lu, Jingjing Li, Xue Xia, Xinglong Han, Wenbo Deng, Guisheng Zhong, Zhen-Ao Zhao, Shijun Hu
Journal: Theranostics (2019)

Rationale: As a hallmark of various heart diseases, cardiac fibrosis ultimately leads to end-stage heart failure. Anti-fibrosis is a potential therapeutic strategy for heart failure. Long noncoding RNAs (lncRNAs) have emerged as critical regulators of heart diseases that promise to serve as therapeutic targets. However, few lncRNAs have been directly implicated in cardiac fibrosis. Methods: The lncRNA expression profiles were assessed by microarray in cardiac fibrotic and remote ventricular tissues in mice with myocardial infarction. The mechanisms and functional significance of lncRNA-AK137033 in cardiac fibrosis were further investigated with both in vitro and in vivo models. Results: We identified 389 differentially expressed lncRNAs in cardiac fibrotic and remote ventricular tissues in mice with myocardial infarction. Among them, a lncRNA (AK137033) we named Safe was enriched in the nuclei of fibroblasts, and elevated in both myocardial infarction and TGF-β-induced cardiac fibrosis. Knockdown of Safe prevented TGF-β-induced fibroblast-myofibroblast transition, aberrant cell proliferation and secretion of extracellular matrix proteins in vitro, and mended the impaired cardiac function in mice suffering myocardial infarction. In vitro studies indicated that knockdown of Safe significantly inhibited the expression of its neighboring gene Sfrp2, and vice versa. The Sfrp2 overexpression obviously disturbed the regulatory effects of Safe shRNAs in both the in vitro cultured cardiac fibroblasts and myocardial infarction-induced fibrosis. Dual-Luciferase assay demonstrated that Safe and Sfrp2 mRNA stabilized each other via their complementary binding at the 3'-end. RNA electrophoretic mobility shift assay and RNA immunoprecipitation assay indicated that RNA binding protein HuR could bind to Safe-Sfrp2 RNA duplex, whereas the knockdown of HuR dramatically reduced the stabilization of Safe and Sfrp2 mRNAs, down-regulated their expression in cardiac fibroblasts, and thus inhibited TGF-β-induced fibrosis. The Safe overexpression partially restrained the phenotype change of cardiac fibroblasts induced by Sfrp2 shRNAs, but not that induced by HuR shRNAs. Conclusions: Our study identifies Safe as a critical regulator of cardiac fibrosis, and demonstrates Safe-Sfrp2-HuR complex-mediated Sfrp2 mRNA stability is the underlying mechanism of Safe-regulated cardiac fibrosis. Fibroblast-enriched Safe could represent a novel target for anti-fibrotic therapy in heart diseases.
Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations
Authors: N.C. Turner, A.D. Laird, M.L. Telli, H.S. Rugo, A. Mailliez, J. Ettl, E.-M. Grischke, L.A. Mina, J. Balmaña, P.A. Fasching, S.A. Hurvitz, L.A. Albacker, G.M. Frampton, J. Chelliserry, P. Bycott, U. Conte, A.M. Wardley, M.E. Robson
Journal: Annals of Oncology (2019)
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
Authors: C.L. Creutzberg, A. Leon-Castillo, S.M. de Boer, M.E. Powell, L.R. Mileshkin, H.J. Mackay, A. Leary, H.W. Nijman, N. Singh, P. Pollock, A. Fyles, C. Haie-Meder, V T H B M Smit, R.J. Edmondson, H. Putter, H.C. Kitchener, E.J. Crosbie, M. de Bruyn, R. Nout, T. Bosse
Journal: Annals of Oncology (2019)
Exosomes in NSCLC as a source of biomarkers
Authors: E. Duréndez, S. Calabuig-Fariñas, C. Suarez, M. Mosqueda, A. Moreno-Manuel, S. Torres Martinez, A. Herreros Pomares, S. Gallach, E. Escorihuela, E. de la Cueva, A. Martinez-Romero, E. Serna, J.M. Paramio, E. Jantus-Lewintre, C.J. Camps Herrero
Journal: Annals of Oncology (2019)
Machine Learning in Epidemiology and Health Outcomes Research
Authors: Timothy L. Wiemken, Robert R. Kelley
Journal: Annual Review of Public Health (2019)

Machine learning approaches to modeling of epidemiologic data are becoming increasingly more prevalent in the literature. These methods have the potential to improve our understanding of health and opportunities for intervention, far beyond our past capabilities. This article provides a walkthrough for creating supervised machine learning models with current examples from the literature. From identifying an appropriate sample and selecting features through training, testing, and assessing performance, the end-to-end approach to machine learning can be a daunting task. We take the reader through each step in the process and discuss novel concepts in the area of machine learning, including identifying treatment effects and explaining the output from machine learning models.
Judge clears way for US’s first drug consumption room
Authors: Elisabeth Mahase
Journal: BMJ (2019)

A judge has ruled that opening a drug consumption room in Philadelphia would not violate federal drug laws.1

The ruling came after the US Justice Department launched a legal challenge in an attempt to stop the non-profit group Safehouse opening a drug consumption room. This would be the first US site where people could go to use illegal opioids under medical supervision.

While the Justice Department argued that such a room would be unlawful, the judge ruled in favour of Safehouse as he said the purpose of such a place would be to “reduce drug use, not facilitate it.”

Deaths from overdoses have been rising across …
Wolff-Parkinson-White Syndrome
Authors: Philippecoumel, Marcwaynberger, Alexandrefabiato, Robertslama, Jacquesaigueperse, Yvesbouvrain
Journal: Circulation (1972)

Total atrioventricular bypass (Kent bundle) does not explain all the findings in some cases of Wolff-Parkinson-White (W-P-W) syndrome. Two cases are reported in which two accessory pathways, set in series or in parallel, could be demonstrated. In case 1, a short P-R interval, gap phenomenon, and presence of delta wave with either a short or long P-R interval suggested the hypothesis of an atrio-His accessory path (James fibers). The presence of a type-B delta wave during His stimulation demonstrated the takeoff of another bypass (Mahaim fibers) below or at the point of stimulation. The His-ventricle accessory path had a supernormal phase of conduction during either atrial or His stimulation. In case 2, the rapid spread of the impulse to the His bundle (P-H 65 msec) was responsible for a normal H-R interval (35 msec) during either reciprocating tachycardia or normal sinus rhythm wtih a nonwidened QRS and minimal W-P-W deformity (partial cancellation of the delta wave). During reciprocating tachycardia, alt...
Sociodemographic Factors in Neovascular Age-Related Macular Degeneration
Authors: Samir N Patel, Connie Wu, Anthony Obeid, Meera Sivalingam, Kalla Gervasio, Turner D Wibbelsman, Hannah Levin, David Xu, Carl D Regillo, Jason Hsu, Allen C Ho
Journal: Ophthalmology (2019)
Validity of surrogate endpoints assessing central venous catheter-related infection: evidence from individual- and study-level analyses
Authors: H.J. de Grooth, J.-F. Timsit, L. Mermel, O. Mimoz, N. Buetti, D. du Cheyron, H.M. Oudemans-van Straaten, J.-J. Parienti
Journal: Clinical Microbiology and Infection (2019)
Abstract 11276: Differentiating Cardiac Fibrosis From Hypertrophy in Chronic Kidney Disease Hemodialysis Patients Using Gadolinium-Free Imaging and Biomarkers of Extracellular Matrix Turnover
Authors: Tori A Stromp, Tyler J Spear, Rebecca M Kidney, Kristin N Andres, Joshua C Kaine, Richard J Charnigo, Steve W Leung, Vincent L Sorrell, Moriel H Vandsburger
Journal: Circulation (2016)

Purpose: Cardiac stress blood biomarkers are typically correlated to hypertrophy or diastolic dysfunction but not fibrosis in chronic kidney disease (CKD). Cardiac fibrosis can be measured without gadolinium as elevated normalized signal difference (ΔS/S o ) between pairs of magnetization transfer (MT) weighted magnetic resonance (MRI) images. We used MT-MRI to compare blood biomarkers to fibrosis, hypertrophy and diastolic strain rate in CKD patients on hemodialysis (CKD5). Hypothesis: Biomarkers of cardiac stress correlate with left ventricular (LV) hypertrophy, not fibrosis, in CKD5 patients. Methods: MT-MRI generated maps of ΔS/S o in 23 CKD5 patients and 21 controls (Fig 1A, B). Fibrotic burden was defined as divergence in ΔS/S o compared to a standard distribution (Fig 1C). In a subset of 12-15 per group, serum troponin T (TnT), fibroblast growth factor 23 (FGF23), matrix metalloproteases (MMP) 2 and 9 and tissue inhibitor of MMP (TIMP) 1 and 2 were measured by ELISA and analyzed with Spearman correlations. Feature tracking measured strain. Results: CKD5 patients had higher ΔS/S o (146.2 ± 18.7%), divergence (10.0 ± 9.2%) and LV mass index (81.6 ± 28.9 g/m 2 ) than controls (133.5 ± 11.5%, 5.4 ± 3.7%, 57.9 ± 15.5 g/m 2 , all p &lt;0.05). Ejection fraction, diastolic strain rate and longitudinal strain were similar. While TnT, FGF23 and TIMP1/2 correlated with mass, only TIMP1 correlated with fibrotic burden (Table 1). Conclusions: Most stress biomarkers correlate with hypertrophy but not fibrosis in CKD5 patients. Activation of cardiac fibroblasts by TIMP1 and correlation of TIMP1 with degree of fibrosis suggest TIMP1 as an alternative target to attenuate cardiac fibrosis in CKD5 patients.
Abstract 16939: Pediatric Quality of Life While Supported With a Ventricular Assist Device
Authors: Jacob R Miller, Umar S Boston, Deirdre J Epstein, Matthew C Henn, Christopher P Lawrance, Jacob Kallenbach, Kathleen E Simpson, Charles E Canter, Pirooz Eghtesady
Journal: Circulation (2014)

Introduction: The Ventricular Assist Device (VAD) has emerged as an important treatment option for bridging pediatric patients with heart failure to transplant. VADs have been shown to improve survival; however, quality of life (QoL) while supported with a pediatric VAD is unknown. Methods: In this prospective study, pediatric patients, and their parents, who underwent VAD placement completed a generic PedsQL 4.0 biweekly until heart transplant or death. Data are reported at last follow-up with a VAD and compared to three previously reported groups: age-matched healthy controls, outpatients with severe heart disease and children after heart transplant. Results: From December 2007 to August 2013, 13 patients received VAD support for at least two weeks and completed a PedsQL. The mean age at implant was 10.0 ± 4.2 years with a median duration of support of 1.6 months (Table 1). Pre-implant INTERMACS profile was 1 for 3/13 (23%) and 2 for 10/13 (77%). Patients self-reported significantly (p&lt;0.05) reduced total and physical QoL scores when compared to each of the three comparison groups. Self-reported psychosocial QoL scores were significantly lower than healthy controls only. Parent proxy-reported scores were significantly lower than all three comparison groups for all three categories (Figure 1). Conclusion: A large deficit exists in the QoL of pediatric patients supported by a VAD compared to outpatient management of severe heart disease or post-heart transplant patients; however, VAD patients do represent a sicker group. Improvements in QoL must be made, as time spent with a VAD is expected to increase. Though a small sample, these data can serve as a baseline for future comparison.
Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2
Authors: R.C. Doebele, R. Dziadziuszko, A. Drilon, A. Shaw, J. Wolf, A.F. Farago, L. Dennis, T. Riehl, B. Simmons, C. Wu, C.-W. Chang, V. Choeurng, T.R. Wilson
Journal: Annals of Oncology (2019)
EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
Authors: Thomas B.L. Lam, Steven MacLennan, Peter-Paul M. Willemse, Malcolm D. Mason, Karin Plass, Robert Shepherd, Ruud Baanders, Chris H. Bangma, Anders Bjartell, Alberto Bossi, Erik Briers, Alberto Briganti, Karel T. Buddingh, James W.F. Catto, Maurizio Colecchia, Brett W. Cox, Marcus G. Cumberbatch, Jeff Davies, Niall F. Davis, Maria De Santis, Paolo Dell’Oglio, André Deschamps, James F. Donaldson, Shin Egawa, Christian D. Fankhauser, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Silke Gillessen, Nikolaos Grivas, Tobias Gross, Jeremy P. Grummet, Ann M. Henry, Alexandre Ingels, Jacques Irani, Michael Lardas, Matthew Liew, Daniel W. Lin, Lisa Moris, Muhammad Imran Omar, Karl H. Pang, Catherine C. Paterson, Raphaële Renard-Penna, Maria J. Ribal, Monique J. Roobol, Morgan Rouprêt, Olivier Rouvière, Gemma Sancho Pardo, Jonathan Richenberg, Ivo G. Schoots, J.P. Michiel Sedelaar, Phillip Stricker, Derya Tilki, Susanne Vahr Lauridsen, Roderick C.N. van den Bergh, Thomas Van den Broeck, Theodorus H. van der Kwast, Henk G. van der Poel, Geert J.L.H. van Leenders, Murali Varma, Philippe D. Violette, Christopher J.D. Wallis, Thomas Wiegel, Karen Wilkinson, Fabio Zattoni, James M.O. N’Dow, Hendrik Van Poppel, Philip Cornford, Nicolas Mottet
Journal: European Urology (2019)
Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007–2014
Authors: Wenjun Fan, Sephy Philip, Craig Granowitz, Peter P. Toth, Nathan D. Wong
Journal: Diabetes Care (2019)

Hypertriglyceridemia (HTG) is common in patients with diabetes, and statins remain the first-line therapy. However, the proportion of patients with diabetes having elevated triglycerides (TGs) on statin treatment and their atherosclerotic cardiovascular disease (ASCVD) risk has not been described. We quantified the prevalence of HTG in U.S. adults with diabetes currently treated versus not treated with statins and the estimated 10-year ASCVD risk.Among 1,448 U.S. adults aged 20 years and over with diabetes (projected to 24.4 million) in the 2007-2014 National Health and Nutrition Examination Survey (NHANES), we compared the prevalence of borderline HTG (TG 150-199 mg/dL) and HTG (TG ≥200 mg/dL) by statin use and LDL cholesterol (LDL-C) levels, and we used logistic regression to identify risk factors for HTG. We also estimated the 10-year ASCVD risk in those without prior ASCVD.The prevalence of borderline HTG and HTG was 20.0% and 19.5%, respectively, in statin users and 20.1% and 25.3%, respectively, in nonstatin users (P < 0.0001). Even among statin users with LDL-C <70 mg/dL, borderline HTG prevalence was 16.8% and HTG prevalence was 16.7%. Approximately 77.5% of those with HTG had an estimated 10-year ASCVD risk of ≥7.5%, with almost 40% of statin users having ASCVD risk ≥20%.Residual HTG occurs in over one-fifth (∼5.5 million) of U.S. adults with diabetes, including those on statin therapy and with well-controlled LDL-C. Over three-quarters of adults with diabetes with HTG are at moderate or high 10-year risk for ASCVD. Greater efforts are needed to promote lifestyle and pharmacologic means to address residual HTG.
A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy
Authors: Regis Peffault De Latour, Lynn Huynh, Jasmina I. Ivanova, Todor Totev, Mehmet Bilginsoy, Joseph H. Antin, Anuja Roy, Mei Sheng Duh
Journal: Blood (2017)
Expression analysis of NHEJ and HR genes in Ewing sarcomas: Indications of DSB repair dysfunction
Authors: A. Kyriazoglou, V. Konteles, M. Liontos, G. Sofianidis, F. Zagouri, K. Koutsoukos, G. Tsironis, A. Tsiara, M. Kaparelou, R. Zakopoulou, A. Cohen, E. Dimitriadis, L. Mahaira, D. Michali, N. Arnogiannaki, K. Stefanaki, M.A.C. Dimopoulos, A. Kattamis
Journal: Annals of Oncology (2019)
Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial
Authors: L. Landi, L. Bonanno, A. Delmonte, P. Maximilian, V. Stati, V. Minotti, C. Bennati, F. D’Incà, M.R. Migliorino, S. Gori, A. Santo, F. Piantedosi, A. Russo, F. Cappuzzo
Journal: Annals of Oncology (2019)
Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy
Authors: S. Calabuig-Fariñas, L. Muinelo-Romay, A. Abalo, R. Lago, M. Mosqueda, C. Rodriguez Lopez, E. Escorihuela, S. Gallach Garcia, J. Garcia, A. Blasco, E. Jantus-Lewintre, R. López, C. Camps
Journal: Annals of Oncology (2019)
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study
Authors: M.A. Fabbri, A. Botticelli, C. Omarini, E. Cretella, A. Fabi, D. Alesini, L. Pizzuti, G. Piesco, A. Vaccaro, F. Atzori, F. Piacentini, L. Moscetti, A. Orlandi, V. Sini, A. Mercanti, M.L. Framarino, M. Persano, R. Ceccherini, E.M. Ruggeri
Journal: Annals of Oncology (2019)
P-Rex1 expression in breast cancer patients
Authors: A. Lara Montero, N. Gonzalez, K. Cicinelli, G. Acosta, S. Vornetti, L. Leguina, D. Maltagliatti, V. Sanchotena, M. Carrasco, D. Flaks, C. Temple, F. Costa, C. Gon, N. Cuneo, M. Abba, E. Kordon, P. Lorenzano, C. Arias, A. De Laurentiis, E. Wertheimer
Journal: Annals of Oncology (2019)
SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase
Authors: M.G. Fakih, D. Wang, W. Harb, L. Rosen, D. Mahadevan, J.D. Berlin, P. Basciano, R. Brown, O. Arogundade, C. Cox, G Di Genova, D. Krige, H. McElwaine-Johnn
Journal: Annals of Oncology (2019)
Identification of a spectrum of germline mutations for hereditary diffuse gastric cancer in the Russian population by next-generation sequencing
Authors: I.U. Efimova, E. Ignatova, I. Bykov, A.I. Kalinkin, A.S. Tanas, E.A. Alekseeva, V.V. Strelnikov, A. Alakunov, E. Kuznetsova, M.V. Nemtsova
Journal: Annals of Oncology (2019)
Is there a role for next-generation sequencing (NGS) profiling on metastatic non-colorectal gastrointestinal carcinomas (MNCGIC) in developing countries? A single center experience
Authors: M F S A Ribeiro, L.L. Gadotti, C. Godoy, A.A.L. Pereira, D. de Freitas, M. Crosara, L. Dib, F.P. Costa, F.C. Capareli, D.L.F. Jardim, B. Gumz, G.S. Fernandes
Journal: Annals of Oncology (2019)
OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
Authors: I.A. McNeish, V. Moreno, G. Jayson, P. Roxburgh, M P Barretina Ginesta, J. Garcia-Donas, A Anton Torres, A. Michael, R. Brown, D. Krige, J. Bendall, G. Di Genova, H. McElwaine-Johnn
Journal: Annals of Oncology (2019)